Compare Citius Pharmaceuticals Inc (CTXR) vs Matson Inc (MATX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Matson Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.49 (market cap $13.62M), while Matson Inc trades at $226.14 (market cap $6.81B). The key difference: Matson Inc is far larger — about 500× Citius Pharmaceuticals Inc's market cap, and Matson Inc pays a 0.67% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and Matson Inc for 23 Days on average.
| CTXR | MATX | |
|---|---|---|
Market Cap | $13.62M | $6.81B |
Volume | 132,438 | 255,080 |
Sector | Health | Industrials |
52-Week High | $1.82 | $238.60 |
52-Week Low | $0.48 | $88.05 |
Typical Hold Time | 16 Days | 23 Days |
Enterprise Value | $3.79M | $7.41B |
Dividend Yield | — | 0.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
Matson (MATX) trades at $222.92, down 0.83% on the day, with technical indicators showing a neutral to bearish short-term bias. The company demonstrates strong fundamental performance with consistent earnings beats, including Q2 2026 EPS of $4.27 versus $3.79 expected, and maintains healthy profitability with a 13.41% net income margin. Recent news highlights institutional buying interest and positive analyst sentiment toward the transportation services sector.
MATX presents a compelling investment case with solid earnings growth, attractive valuation metrics (P/E of 15.37), and strong analyst support (66.7% buy ratings). Key risks include freight market volatility and competitive pressures, but the company's raised full-year outlook and dividend payments provide stability. The stock offers potential upside with Wall Street analysts projecting 27.3% price target upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Matson Inc
Matson, Inc. is an American shipping and logistics company primarily operating in the Pacific. The company provides ocean transportation services, including container, automobile, and general cargo, particularly between the U.S. West Coast, Hawaii, Alaska, and Guam. Matson also offers logistics services, including warehousing, less-than-container load (LCL) consolidation, and supply chain management, making it a critical service provider for businesses operating across the Pacific region.
Read more on MATX →
